Navigation Links
Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Today, Genencor, a division of Danisco A/S, launched Accellerase(R) 1500, the next generation of its cellulosic ethanol enzyme product. Genencor introduced the product at the Renewable Fuels Association (RFA) 2009 National Ethanol Conference in San Antonio, TX.

Accellerase(R) 1500 is another significant step toward commercialization of biofuels and other biochemicals made from cellulosic feedstocks, such as agricultural residues and bioenergy crops. It also reinforces Genencor's position as a global leader in 2nd generation ethanol innovation.

"We're on course to fast-track commercialization of cellulosic ethanol," says Philippe Lavielle, Senior Vice President, Business Development, Genencor. "Accellerase was a breakthrough in the industry. Now, by launching this improved enzyme product, we reach another important technical milestone toward commercial-scale production of transportation fuel and other biochemicals from renewable, non-food feedstocks."

Accellerase(R) 1500 will lower one of the major cost hurdles to producing ethanol or biochemicals from cellulosic feedstocks, such as corn stover, sugarcane bagasse, wood chips, wheat straw, and switchgrass. In addition, Accellerase(R) 1500 has a significantly improved formulation and higher activity resulting in higher ethanol yields and robust operation in a wider variety of processes. The product is based on Genencor's patented gene expression technology and the division's 25-year history of biofuels research.

Accellerase(R) is critical to the hydrolysis step of converting biomass to ethanol or other biochemicals. In this step, plant material is broken down into sugars for fermentation to ethanol.

Genencor supplies Accellerase(R) as part of its dual-strategy to drive forward the cellulosic ethanol industry, which includes its dedicated enzyme business, and its joint venture DuPont Danisco Cellulosic Ethanol LLC (DDCE), which develops and provides integrated technology packages for biomass ethanol production.

Genencor, a division of Danisco A/S, is a world leader in industrial biotechnology and a pioneer in enzyme innovation. Genencor improves process and product performance for a spectrum of industries, from biofuels and laundry detergents to animal nutrition and food. As part of a large global organization, Genencor has a manufacturing and distribution network that spans more than 40 countries. In collaboration with customers, technology leaders and other stakeholders, Genencor supplies competitive, biobased solutions. These innovations create value throughout the supply chain, from raw material to finished product.

SOURCE Genencor
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont and Genencor Create World-Leading Cellulosic Ethanol Company
2. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
3. Genencor Appoints New Executive Vice President - Technical Enzymes
4. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
5. EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention
6. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
7. CUREXO Technology Corporation Launches Its ROBODOC(R) Surgical System at Upcoming Orthopaedic Conference in Las Vegas
8. Launches a New Season of Industry Career Fairs
9. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
10. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):